Literature DB >> 26963458

Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.

Pouya Ziai1, Mohammad Reza Hayeri1, Aliaksei Salei1, Ali Salavati1, Sina Houshmand1, Abass Alavi1, Oleg M Teytelboym1.   

Abstract

The combination of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and computed tomography (CT) for dual-modality imaging (PET/CT) plays a key role in the diagnosis and staging of FDG-avid malignancies. FDG uptake by the tumor cells offers an opportunity to detect cancer in organs that appear normal at anatomic imaging and to differentiate viable tumor from posttreatment effects. Quantification of FDG uptake has multiple clinical applications, including cancer diagnosis and staging. Dedicated FDG PET/CT-based visual and quantitative criteria have been developed to evaluate treatment response. Furthermore, the level of tumor FDG uptake reflects the biologic aggressiveness of the tumor, predicting the risk of metastasis and recurrence. FDG uptake can be measured with qualitative, semiquantitative, and quantitative methods. Qualitative or visual assessment of PET/CT images is the most common clinical approach for describing the level of FDG uptake. Standardized uptake value (SUV) is the most commonly used semiquantitative tool for measuring FDG uptake. SUV can be measured as maximum, mean, or peak SUV and may be normalized by using whole or lean body weight. SUV measurements provide the basis for quantitative response criteria; however, SUVs have not been widely adopted as diagnostic thresholds for discriminating malignant and benign lesions. Volumetric FDG uptake measurements such as metabolic tumor volume and total lesion glycolysis have shown substantial promise in providing accurate tumor assessment. SUV measurement and other quantification techniques can be affected by many technical, physical, and biologic factors. Familiarity with FDG uptake quantification approaches and their pitfalls is essential for clinical practice and research. (©)RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26963458     DOI: 10.1148/rg.2016150102

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  18 in total

1.  Quantification of [18F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value.

Authors:  Maria Elisa Serrano; Mohamed Ali Bahri; Guillaume Becker; Alain Seret; Frédéric Mievis; Fabrice Giacomelli; Christian Lemaire; Eric Salmon; André Luxen; Alain Plenevaux
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

2.  Thalamic and basal ganglia metabolism on interictal 18F-FDG PET in temporal lobe epilepsy: an SUV-based analysis.

Authors:  Aditya Jain; Aaron F Struck; Kaitlin M Woo; Christine J Jaskowiak; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

Review 3.  [18F]FDG-PET Evaluation of Spinal Pathology in Patients in Oncology: Pearls and Pitfalls for the Neuroradiologist.

Authors:  P Y Patel; I Dalal; B Griffith
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-28       Impact factor: 3.825

4.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

5.  Novel non-invasive assessment of upper airway inflammation in obstructive sleep apnea using positron emission tomography/magnetic resonance imaging.

Authors:  Oren Cohen; Mira M John; Audrey E Kaufman; Vaishnavi Kundel; Omar Burschtin; Samira Khan; Zahi Fayad; Venkatesh Mani; Neomi A Shah
Journal:  Sleep Breath       Date:  2021-08-26       Impact factor: 2.655

6.  Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Authors:  Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

7.  Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy.

Authors:  Mark K Farrugia; Sinjen Wen; Geraldine M Jacobson; Mohamad Adham Salkeni
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

Review 8.  Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Authors:  Charlotte Lees; Colm Keane; Maher K Gandhi; Jay Gunawardana
Journal:  Br J Haematol       Date:  2019-02-10       Impact factor: 6.998

9.  Assessing and reducing PET radiotracer infiltration rates: a single center experience in injection quality monitoring methods and quality improvement.

Authors:  Dustin R Osborne; Shelley N Acuff; Michael Fang; Melissa D Weaver; Yitong Fu
Journal:  BMC Med Imaging       Date:  2020-01-10       Impact factor: 1.930

10.  Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival.

Authors:  Eirini Polymeri; May Sadik; Reza Kaboteh; Pablo Borrelli; Olof Enqvist; Johannes Ulén; Mattias Ohlsson; Elin Trägårdh; Mads H Poulsen; Jane A Simonsen; Poul Flemming Hoilund-Carlsen; Åse A Johnsson; Lars Edenbrandt
Journal:  Clin Physiol Funct Imaging       Date:  2019-12-20       Impact factor: 2.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.